Verified Nov 2026
Other
·
Nashville, Tennessee
·
Since 2012
Harrow is an eyecare pharmaceutical company headquartered in Nashville, Tennessee, founded in 2012 and employing between 200 and 500 people. It is publicly traded on NASDAQ under the ticker HROW. The company develops, commercializes, and manages branded and compounded ophthalmic medications for conditions including dry eye disease, glaucoma, and infections, and serves ophthalmologists, optometrists, and surgical centers. In August 2026, it announced the acquisition of global rights to TYRVAYA®, an FDA-approved nasal spray for dry eye disease.
Harrow at a glance
Revenue
268.7M
Employees
200-500
Founded
2012
Headquarters
Nashville, Tennessee
Ownership
Publicly traded (NASDAQ: HROW)
Import activity
444
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
444
Named foreign suppliers
50
Top origins
Taiwan · China · South Korea · Singapore
Shared foreign counterparties do not establish that these companies buy from Harrow.
What this tells a buyer
The company announced the acquisition of global rights to TYRVAYA® in August 2026 and completed that acquisition in October 2026.
Harrow's ophthalmic portfolio includes branded FDA-approved drugs and compounded medications, with a listed product in suspension form.
Harrow reported a revenue band of approximately $268.7 million and is listed on NASDAQ under the ticker HROW.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
Overview
Harrow is an eyecare pharmaceutical company headquartered in Nashville, Tennessee, founded in 2012 and employing between 200 and 500 people. It is publicly traded on NASDAQ under the ticker HROW. The company develops, commercializes, and manages branded and compounded ophthalmic medications for conditions including dry eye disease, glaucoma, and infections, and serves ophthalmologists, optometrists, and surgical centers. In August 2026, it announced the acquisition of global rights to TYRVAYA®, an FDA-approved nasal spray for dry eye disease.
At a glance
Attribute | Detail |
|---|---|
Founded | 2012 |
Headquarters | Nashville, Tennessee |
Employees | 200-500 |
Revenue | 268.7M |
Ownership | Publicly traded (NASDAQ: HROW) |
What Harrow makes
Harrow's ophthalmic portfolio includes branded FDA-approved drugs and compounded medications, with a listed product in suspension form.
Products and capabilities described on the company's own site include Suspension (source: harrow.com).
Trade and customs footprint
The company announced the acquisition of global rights to TYRVAYA® in August 2026 and completed that acquisition in October 2026. US customs bill-of-lading records list 444 inbound shipments across 50 foreign suppliers, with top origins including Taiwan · China · South Korea · Singapore.
Latest developments
2026-11-02 — Harrow Launches HarrowRx Platform | Markets Insider (businessinsider.com)
2026-10-05 — Harrow Closes Acquisition of TYRVAYA® (globenewswire.com)
2026-08-06 — Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease | Harrow, Inc. (harrow.com)
2026-03-24 — Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030 | Harrow, Inc. (harrow.com)
2025-09-26 — Harrow to Acquire Melt Pharmaceuticals | Harrow, Inc. (harrow.com)
2025-09-25 — Harrow Launches Harrow Access for All (HAFA) | Harrow, Inc. (harrow.com)
Company details
Harrow reported a revenue band of approximately $268.7 million and is listed on NASDAQ under the ticker HROW. Harrow was founded in 2012, has an estimated 200-500 employees, and is headquartered in Nashville, Tennessee.
Frequently asked questions
What does Harrow do?
Harrow is an eyecare pharmaceutical company headquartered in Nashville, Tennessee, founded in 2012 and employing between 200 and 500 people. It is publicly traded on NASDAQ under the ticker HROW. The company develops, commercializes, and manages branded and compounded ophthalmic medications for conditions including dry eye disease, glaucoma, and infections, and serves ophthalmologists, optometrists, and surgical centers. In August 2026, it announced the acquisition of global rights to TYRVAYA®, an FDA-approved nasal spray for dry eye disease.
Where is Harrow headquartered?
Harrow is headquartered in Nashville, Tennessee (1 Burton Hills Blvd, Nashville, Tennessee, 37215-6100).
When was Harrow founded?
Harrow was founded in 2012.
How big is Harrow?
Harrow has an estimated 200-500 employees, with revenue in the 268.7M range.
Is Harrow publicly traded?
Publicly traded (NASDAQ: HROW). Public financial figures are drawn from its filings.
Does Harrow import from overseas suppliers?
US customs bill-of-lading records show 444 inbound shipments for Harrow, with top origins including Taiwan · China · South Korea · Singapore.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.